Integra LifeSciences Holdings Corporation
IART · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | -0.00 | 0.07 | -0.08 |
| FCF Yield | 9.20% | -0.25% | -2.39% | 0.64% |
| EV / EBITDA | 20.00 | -5.79 | -223.35 | 44.05 |
| Quality | ||||
| ROIC | 0.96% | -13.89% | -0.35% | 0.82% |
| Gross Margin | 56.24% | 50.37% | 55.25% | 56.27% |
| Cash Conversion Ratio | -7.57 | -0.02 | 0.45 | 2.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.12% | 1.62% | 1.32% | 1.12% |
| Free Cash Flow Growth | 4,429.73% | 94.18% | -459.14% | 256.22% |
| Safety | ||||
| Net Debt / EBITDA | -0.35 | -3.80 | -114.85 | 21.97 |
| Interest Coverage | 1.77 | -24.36 | -0.77 | 1.88 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.44 | 0.38 | 0.45 |
| Cash Conversion Cycle | 308.86 | 224.05 | 245.50 | 216.52 |